Complement activation by cross-linked truncated and chimeric full-length beta-amyloid

Neuroreport
D H CribbsA J Tenner

Abstract

The activation of complement by beta-amyloid (A beta) has been implicated in the local inflammatory response in Alzheimer's disease. To assess the structural parameters required for this activation, beta-sheet-containing fibrils of A beta1-28 were induced by low pH and then chemically cross-linked to constrain the beta-sheet conformation. Chimeric A beta peptides with a substituted C-terminal sequence derived from two different transmembrane proteins were also assessed for the ability to form fibrils rich in beta-sheet structure and to activate complement. Both the cross-linked A beta1-28 and the chimeric A beta peptides were strong activators of the classical complement pathway. These results suggest that the C-terminal residues (29-42) of A beta facilitate fibril assembly required for complement activation but do not contain the interaction sites required for complement activation, further supporting the hypothesis that C1q binds to the N-terminal hydrophilic domain of A beta, and that a fibrillar beta-sheet-rich conformation is required for effective binding and activation of C1.

References

Jul 1, 1992·Research in Immunology·P L McGeer, E G McGeer
Jan 1, 1982·Acta Neuropathologica·P Eikelenboom, F C Stam
Feb 1, 1995·Molecular Neurobiology·C W Cotman, A J Anderson
Sep 1, 1994·Journal of Neuropathology and Experimental Neurology·D J Selkoe
Jul 1, 1996·Drugs & Aging·F L Van Muiswinkel, P Eikelenboom
Jul 1, 1996·Drugs & Aging·J B Schwartz
Sep 1, 1996·Neurobiology of Aging·P Eikelenboom, R Veerhuis
Sep 1, 1996·Neurobiology of Aging·C W CotmanB J Cummings

❮ Previous
Next ❯

Citations

Sep 13, 2001·Mental Retardation and Developmental Disabilities Research Reviews·I T Lott, E Head
Nov 5, 2003·Brain Research Bulletin·Angela ConteDavide Tagliazucchi
Nov 14, 2000·Molecular Immunology·B T Messmer, D S Thaler
Dec 10, 1999·Neurobiology of Aging·S D WebsterD H Cribbs
Jul 27, 2001·Brain Research Bulletin·A CampbellG Perry
Feb 27, 1999·Current Opinion in Immunology·A Nicholson-Weller, L B Klickstein
Feb 10, 2000·The American Journal of Pathology·S E StoltznerC A Lemere
Jun 8, 2000·Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis·H LeVine
Jul 6, 2000·Japanese Journal of Pharmacology·K SugayaH Manev
May 22, 2001·Medical Hypotheses·A Campbell
Jul 31, 1999·Journal of Neurochemistry·E García de YébenesM Blum
Nov 21, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·P Tacnet-DelormeG J Arlaud
Jan 8, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Andrea J Tenner
Jun 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·S D WebsterA J Tenner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.